Adalimumab (Humira) for moderate to severe psoriatic arthritis - horizon scanning review
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
NHSC. Adalimumab (Humira) for moderate to severe psoriatic arthritis - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2004
This study aims to summarise the currently available evidence on adalimumab (Humira) for moderate to severe psoriatic arthritis.
Adalimumab (Humira) is a fully human anti-TNF-a monoclonal antibody in phase III trials for reducing the signs and symptoms of active psoriatic arthritis (PsA) in adults. It is anticipated that adalimumab will be administered by subcutaneous injection once a fortnight at a dose of 40mg. There are currently no published abstracts or results of clinical trials in psoriatic arthritis. Adalimumab is currently licensed for use in rheumatoid arthritis, and is in phase III trials for juvenile idiopathic arthritis, ankylosing spondylitis, chronic-plaque psoriasis and Crohns disease.